Active — Not RecruitingPhase 4

Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.

Egypt28 participantsStarted 2023-09-01

Plain-language summary

The study compares the efficacy and safety of intralesional bevacizumab versus corticosteroids for the treatment of keloids. Assessment will be done clinically by the use of Modified Vancouver Scar Scale. Erythema index will be measured by spectrophotometry. The levels of Vascular Endothelial Growth Factor, collagen type 1 and collagen type 3 in the lesions before and after each treatment modality.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with keloids (post-traumatic, any site, any duration) * Age \>18 years * Patients who didn't receive any treatment for the lesions in the past 6 weeks Exclusion Criteria: * Patients who are pregnant, willing to get pregnant or lactating * History of any liver or renal disease * History of any cardiovascular disease * History of hypertension * History of thrombo-embolic events * Known cases of bleeding disorders * History of peptic ulcer * Patients who underwent any surgeries in the last month

What they're measuring

Modified Vancouver scar scale (mVSS)

Timeframe: 6 months

Erythema Index

Timeframe: 6 months

Vascular Endothelial growth factor (VEGF)

Timeframe: 6 months

Collagen type 1 and 3

Timeframe: 6 months

Histopathological examination

Timeframe: 6 months

Trial details

NCT IDNCT07014280

SponsorKasr El Aini Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-01

View on ClinicalTrials.gov More Keloids trials